UK-EU Device Recognition and FDA Hiring: The Regulatory Reset

The regulatory landscape for medical device manufacturers is experiencing its most significant recalibration in years. This week brought two developments that, when viewed together, fundamentally alter how device companies should think about UK and US market access: MHRA's consultation on indefinite CE mark recognition in Great Britain, and FDA's commitment to substantial reviewer hiring under the emerging MDUFA VI agreement. These aren't isolated policy updates—they represent a coordinated transatlantic effort to balance regulatory burden with patient access, and they demand immediate strategic reassessment from regulatory affairs teams.

The UK's Pragmatic Pivot: From UKCA Ambition to CE Recognition

MHRA's public consultation on indefinitely recognising EU CE-marked devices in Great Britain marks a dramatic departure from the post-Brexit trajectory we've been following since 2021. The original plan—requiring UKCA marking for all devices by a series of staggered deadlines—created a dual-certification burden that was commercially unsustainable for all but the largest manufacturers. The question was never whether this approach would change, but when and how.

What makes this consultation significant isn't just the policy reversal—it's the permanence being proposed. 'Indefinite recognition' isn't another transitional arrangement or deadline extension. It's an acknowledgment that for a market of the UK's size, maintaining a completely parallel regulatory infrastructure delivers diminishing returns. MHRA has been clear that this doesn't mean abandoning UK regulatory sovereignty; rather, it's about focusing resources where they create genuine value: vigilance, post-market surveillance, and innovative pathways like the AI Airlock programme receiving £3.6 million in new funding.

The consultation sets out multiple options, and the devil will be in the detail of conditions attached to CE mark recognition. Will there be requirements for UK Responsible Persons? Will certain device classes face additional scrutiny? Will software and AI-driven devices have separate pathways? These questions matter enormously for resource planning. But the strategic signal is unmistakable: MHRA is prioritising practical market access over regulatory distinctiveness, and that's a win for manufacturers who've been maintaining dual quality systems at considerable expense.

This also strengthens the UK's positioning in its transatlantic regulatory partnership with FDA. By reducing friction in the EU-UK pathway, MHRA can dedicate more attention to the US collaboration announced this week—supporting faster access to innovative technologies in both markets through aligned review processes and information sharing. It's regulatory realpolitik: focus limited resources on relationships and innovations that matter most.

FDA's MDUFA VI Commitment: Addressing the Review Bottleneck

Simultaneously, FDA's announcement that it intends to hire 'substantial numbers' of medical device review staff under the emerging MDUFA VI agreement addresses the industry's most persistent complaint: review timelines that undermine competitiveness and delay patient access. The agreement, nearing finalisation between FDA and industry, represents a recalibration of the user fee programme that's funded device reviews since 1992.

The staffing commitment is significant because it acknowledges what the data has shown for years: FDA's device review capacity hasn't kept pace with submission volume or complexity. As devices incorporate more software, AI, and digital health components, reviews require deeper technical expertise and cross-disciplinary evaluation. Legacy staffing models simply cannot deliver the timelines that make US market entry commercially viable, particularly for smaller innovators.

But new reviewers alone won't solve the problem—they need to be the right reviewers, properly trained, and integrated into modernised review processes. MDUFA VI will likely include performance commitments around review timelines, increased opportunities for early engagement through pre-submission meetings, and potentially new pathways for lower-risk digital health technologies. For manufacturers, this means the calculus around US market entry timing and resource allocation is about to shift.

The UK-US partnership announcement adds another dimension: regulatory alignment between MHRA and FDA on innovative technologies could create de facto harmonisation benefits. If both agencies are evaluating similar devices with shared information and coordinated approaches, manufacturers could see reduced duplication in evidence requirements and faster parallel approvals. This is particularly relevant for AI and software-driven devices where the AI Airlock programme gives MHRA practical evaluation experience that FDA can learn from.

What This Means for Your Team

For regulatory affairs and quality assurance teams, these developments require immediate strategic review across three dimensions: market access planning, resource allocation, and regulatory intelligence.

First, revisit your UK market access strategy now, not when the consultation closes. If indefinite CE recognition becomes policy, the business case for UKCA certification collapses for most manufacturers. That means quality management system resources currently dedicated to UKCA preparation can be redirected—but it also means you need scenario planning for different consultation outcomes. Participate in the consultation if your organisation has relevant expertise or concerns; MHRA has consistently demonstrated willingness to refine policy based on substantive industry input.

Second, reconsider your US market entry timing and resourcing. If FDA review capacity genuinely increases under MDUFA VI, and if early engagement opportunities expand, the traditional wisdom about US submission timing may no longer hold. For devices where US approval has been delayed due to capacity concerns rather than technical issues, this could accelerate timelines by 6-12 months. That has profound implications for commercialisation plans, investor timelines, and competitive positioning. It also means pre-submission meetings and Q-Submissions become even more valuable—FDA's expanded staff will need clear, well-structured early engagement to deliver on faster timelines.

Third, monitor the UK-US partnership for practical harmonisation opportunities. While regulatory alignment won't happen overnight, if both agencies begin accepting similar real-world evidence, share assessment reports, or coordinate on novel device evaluations, your evidence generation strategy and clinical development programmes should reflect those efficiencies. This is particularly critical for digital health and AI technologies where regulatory precedents are still being established.

For startups and smaller manufacturers, these changes are disproportionately beneficial. The dual certification burden has been an existential challenge for companies with limited regulatory budgets. If UK market access becomes simpler and US reviews become faster, the resource cliff between CE marking and global commercialisation becomes significantly more manageable. That said, don't mistake simplified access for reduced regulatory rigour—post-market surveillance, clinical evidence requirements, and quality system expectations aren't being relaxed, just the bureaucratic overhead around parallel certifications.

Key Takeaways

• MHRA's consultation on indefinite CE mark recognition represents a permanent policy shift, not another transitional arrangement—review your UKCA certification strategy immediately
• FDA's MDUFA VI staffing commitment could materially improve US review timelines if accompanied by process improvements and expanded pre-submission engagement opportunities
• The UK-US regulatory partnership creates potential for practical harmonisation on innovative devices, particularly AI and digital health technologies—watch for aligned evidence requirements
• Resource allocation between UKCA and US market preparation should be reassessed based on these developments, with scenario planning for different consultation outcomes

The convergence of these regulatory developments isn't coincidental—it reflects a broader recognition that regulatory systems must evolve to match the pace of medical technology innovation. For regulatory affairs professionals, this is the moment to move from reactive compliance to strategic positioning. The companies that will win in this new environment are those that recognise these policy shifts as opportunities to accelerate access, not just reduce burden. At SMEDTEC, we're helping clients navigate exactly these strategic inflection points—because in regulatory affairs, timing and interpretation matter as much as compliance itself.